Hema.to

Analyze FCS and LMD data with CellStudio, an AI-powered flow cytometry application for cell type predictions, expert review, quality checks, and reporting.

CellStudio was presented at the 2nd International Congress of the Asociación Costarricense de Hematología in San José from May 20 to 22, 2026.

hema.to attended the congress of the French Association of Cytometry in Dijon from November 25 to 28, 2025.

hema.to will attend AFC-SIC in Granada from November 25 to 27, 2026.

hema.to provides events, news, research, and publications about AI-powered cytometry.

hema.to’s 2022 update covers achieving FDA compliance as a Class I device and the regulatory work behind it.

hema.to closed a €3.7 million seed round led by Elaia Partners, with Heal Capital and HTGF, to advance AI software for immune medicine.

hema.to's €3.6 million financing round led by LUMO Labs supports the development and adoption of AI-powered cytometry technology.

hema.to’s 2022 CE mark announcement details the quality, risk, usability, and software standards covered by the work.

hema.to offers positions for a team developing AI-assisted cytometry solutions for high-throughput laboratories.

hema.to develops AI-powered cytometry software.

Answers about CellStudio, AI-assisted flow cytometry analysis, data security, support, and regulatory status.

CellStudio provides AI-powered flow cytometry analysis.

Flow cytometry analysis software, re-imagined. From raw FCS and LMD data to finalized report with AI-powered CellStudio.

hema.to’s Data Processing Addendum outlines the processing and protection of customer data.

hema.to’s company information and privacy policy describe how personal data is processed and protected.

Find hema.to's legal notice, privacy policy, and Data Processing Addendum.